Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Chi-Med Approved to Market Surufatinib for Neuroendocrine Tumors

publication date: Dec 30, 2020

Hutchison China MediTech (Chi-Med) announced surufatinib was approved in China to treat non-pancreatic neuroendocrine tumors (NETs). Surufatinib has a dual mechanism, inhibiting angiogenesis and promoting tumor-associated macrophages. Chi-Med expects it will have synergistic effects when paired with other immunotherapies. Surufatinib, which will be marketed in China under the brand name Sulanda®,is the second Chi-Med product to reach commercialization. The first was fruquintinib in 2018, marketed as Elunate®, a treatment for colorectal cancer. More details....

Stock Symbols: (NSDQ/AIM: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital